Outlook Therapeutics, Inc. Common Stock
Here’s whether Outlook Therapeutics, Inc. Common Stock (OTLK) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-10.98% over 10 days); RSI 73 — overbought, elevated pullback risk; weak 1-year return of -77.4%; 3-month momentum negative (-43.4%); rising volume on a downtrend (distribution, 1.27x avg). Currently 90.9% off its 52-week high. Score: -7/7.
OTLK is trading below its 200-day MA ($1.20) — a key warning sign the longer-term trend is under pressure. With an RSI of 73.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -77.4% compares to +35.1% for SPY (trailed the market by 112.5%). The current 90.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.